0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Article |

Risk Factors for Lymphedema in a Prospective Breast Cancer Survivorship Study:  The Pathways Study FREE

Marilyn L. Kwan, PhD; Jeanne Darbinian, MS, RD; Kathryn H. Schmitz, PhD; Rebecca Citron; Paula Partee, MPH; Susan E. Kutner, MD; Lawrence H. Kushi, ScD
[+] Author Affiliations

Author Affiliations: Division of Research, Kaiser Permanente Northern California, Oakland (Drs Kwan and Kushi and Mss Darbinian, Citron, and Partee); Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia (Dr Schmitz); and San Jose Medical Center, Kaiser Permanente Northern California, San Jose (Dr Kutner).


Arch Surg. 2010;145(11):1055-1063. doi:10.1001/archsurg.2010.231.
Text Size: A A A
Published online

Objective  To determine the incidence of breast cancer–related lymphedema (BCRL) during the early survivorship period as well as demographic, lifestyle, and clinical factors associated with BCRL development.

Design  The Pathways Study, a prospective cohort study of breast cancer survivors with a mean follow-up time of 20.9 months.

Setting  Kaiser Permanente Northern California medical care program.

Participants  We studied 997 women diagnosed from January 9, 2006, through October 15, 2007, with primary invasive breast cancer and who were at least 21 years of age at diagnosis, had no history of any cancer, and spoke English, Spanish, Cantonese, or Mandarin.

Main Outcome Measure  Clinical indication for BCRL as determined from outpatient or hospitalization diagnostic codes, outpatient procedural codes, and durable medical equipment orders.

Results  A clinical indication for BCRL was found in 133 women (13.3%), with a mean time to diagnosis of 8.3 months (range, 0.7-27.3 months). Being African American (hazard ratio, 1.93; 95% confidence interval, 1.00-3.72) or more educated (P for trend = .03) was associated with an increased risk of BCRL. Removal of at least 1 lymph node (hazard ratio, 1.04; 95% confidence interval, 1.02-1.07) was associated with an increased risk, yet no significant association was observed for type of lymph node surgery. Being obese at breast cancer diagnosis was suggestive of an elevated risk (hazard ratio, 1.43; 95% confidence interval, 0.88-2.31).

Conclusions  In a large cohort study, BCRL occurs among a substantial proportion of early breast cancer survivors. Our findings agree with those of previous studies on the increased risk of BCRL with removal of lymph nodes and being obese, but they point to a differential risk according to race or ethnicity.

Figures in this Article

Breast cancer survival rates have been increasing during the past decade,1 resulting in more long-term health consequences of breast cancer treatment. With incidence rates of approximately 26% 2 years after surgery, at least 400 000 women may be currently living with breast cancer–related lymphedema (BCRL),2 the disruption of lymph transport leading to constant buildup of protein-rich fluid within the subcutaneous tissue of the arm, hand, and/or chest.35 Possible risk factors include the degree of axillary dissection, radiation therapy, obesity at diagnosis, older age, postoperative fluid formation, and infection in the arm.6

Reports of BCRL incidence vary widely owing to nonstandard diagnostic methods, type of cancer therapy, and follow-up after treatment.4 Incidence ranges from 10% to 56% after axillary lymph node dissection (ALND), 0% to 23% after sentinel lymph node biopsy (SLNB), and 21% to 51% after axillary radiation therapy and lymph node surgery.2,7 The prevalence increases with time since treatment.8,9 In addition, BCRL can cause functional impairment of the affected arm10,11 and psychological morbidity,1214 both of which can lead to an overall decreased quality of life.9,1518

Given the limited number of prospective studies examining determinants of BCRL, we initiated a prospective cohort study among patients recently diagnosed as having breast cancer within Kaiser Permanente Northern California (KPNC). The Pathways Study is one of the first to systematically examine the incidence of BCRL as well as demographic, lifestyle, and clinical factors associated with its development. We present data from the first 997 enrolled participants with a mean follow-up time of 20.9 months.

STUDY COHORT

The Pathways Study is an ongoing prospective cohort study actively recruiting women from the KPNC patient population recently diagnosed as having invasive breast cancer. As of January 30, 2009, 2415 patients have been enrolled since recruitment began on January 9, 2006, with a mean time from breast cancer diagnosis to enrollment of 1.9 months (range, 0.3-7.3 months). Participants are largely representative of the overall KPNC breast cancer population yet are slightly younger and more likely to be diagnosed as having earlier-stage disease, as described elsewhere.19 Cases are rapidly ascertained on a daily basis by automatic scanning of electronic pathologic reports, with subsequent verification of cancer diagnosis and patient notification by a medical records analyst. Eligibility criteria include current KPNC membership, age of at least 21 years at diagnosis, recent diagnosis of primary invasive breast cancer (all stages), no history of any cancer, and ability to speak English, Spanish, Cantonese, or Mandarin. Written informed consent is obtained from participants before commencement of the in-person interview. The study was approved by the institutional review boards of all collaborating institutions.

DATA COLLECTION
BCRL Diagnosis and Treatment

Diagnosis of BCRL requires consideration of multiple clinical factors, including postsurgical transient swelling (not considered lymphedema). The classic manifestation of lymphedema is defined by swelling.20 However, more recent guidelines in the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.021 acknowledge that lymphedema includes not only swelling but also tissue tone and texture. Diagnosis requires examination by a specialist trained as recommended by the National Lymphedema Network.22

Using KPNC electronic medical records, a diagnosis of lymphedema was determined from 3 sources: (1) outpatient or hospitalization International Classification of Diseases, Ninth Revision,23 diagnostic codes 457.0 (postmastectomy lymphedema syndrome) and 457.1 (other lymphedema, including acquired [chronic]); (2) outpatient procedural codes corresponding to lymphedema treatment and duration of the procedure, such as manual lymph drainage (Current Procedural Terminology -4 code 97140 and internal KPNC qualifiers signifying duration) and compression wrap (Current Procedural Terminology -4 code 97139 [https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp] and internal KPNC qualifiers signifying duration); and (3) durable medical equipment (DME) orders associated with BCRL. Relevant events must have occurred after the primary breast cancer diagnosis. Women were excluded if they had a history of lymphedema diagnosis, procedures, or DME orders.

For the analysis, 3 definitions of a BCRL diagnosis were developed: (1) transient and persistent lymphedema: an outpatient clinic or hospitalization diagnosis, BCRL procedure, or DME order anytime after breast cancer diagnosis, (2) persistent lymphedema: an outpatient clinic or hospitalization diagnosis, BCRL procedure, or DME order at least 3 months after definitive breast cancer surgery, and (3) persistent lymphedema: an outpatient clinic or hospitalization diagnosis anytime after definitive breast cancer surgery followed by a BCRL procedure or DME order.

Demographic and Lifestyle Data

During the interview, demographic information (age at breast cancer diagnosis, race/ethnicity, educational level, marital status, and annual household income) as well as lifestyle factors (body mass index [BMI; calculated as weight in kilograms divided by height in meters squared], smoking status, and physical activity) were obtained. The BMI was calculated from self-reported weight and height, and missing values were supplemented by concurrent data from KPNC electronic medical records. Physical activity in metabolic equivalent tasks (hours per week) was assessed from a previously validated, self-administered questionnaire.24

Clinical Data

Using KPNC electronic medical records, data on breast surgery (lumpectomy and mastectomy) and lymph node surgery (ALND and SLNB) were obtained using International Classification of Diseases, Ninth Revision23 (85.20-85.23, 85.33-85.48, 40.23, 40.3, and 40.51) and Current Procedural Terminology -4 (19120-19240, 19301-19307, 19340-19342, 38500-38530, 38740, 38745, and 38792) diagnostic codes. Number of lymph nodes removed during the definitive surgery was abstracted from pathology reports by a trained staff member (R.C.). Data on number of positive nodes, American Joint Committee on Cancer (AJCC) stage, and chemotherapy and radiation therapy were obtained from the KPNC Cancer Registry.25 Data were collected, coded, and added to the KPNC Cancer Registry approximately 4 months after diagnosis to allow for the completion of treatment. Radiation therapy data were supplemented by other electronic sources. Information on adjuvant hormone therapy was abstracted from outpatient pharmacy records.

STATISTICAL METHODS AND DATA ANALYSIS

Our analysis is based on the first 997 women enrolled in the Pathways Study with complete demographic, lifestyle, and clinical data. Relevant characteristics, as determined a priori from previous literature and current hypotheses, between women who developed BCRL and those who did not were compared using Pearson χ2 tests (categorical variables) and Satterthwaite t tests (continuous variables). Follow-up began on the date of initial breast cancer diagnosis and continued until BCRL diagnosis or July 31, 2008, whichever occurred first; women were censored on the date of death or disenrollment from the KPNC medical care program (defined as first occurrence of a gap in coverage greater than 90 days).

The Kaplan-Meier method was used to generate a cumulative incidence curve26 from initial breast cancer diagnosis to occurrence of BCRL in the cohort by plotting the complement of the survival function estimates. Initially, univariate Cox proportional hazards models27 were constructed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for each selected demographic, lifestyle, and clinical factor and risk of BCRL as defined previously. Subsequently, only variables that retained a priori interest and/or statistical significance were included in 3 final multivariate models, with each model estimating the associations between the selected covariates (adjusted for each other) and 1 of the 3 definitions of BCRL diagnosis. Linear tests of trend were estimated by modeling continuous predictor variables (age, BMI, and physical activity) and categorical predictor variables (household income) on an ordinal scale. All analyses were performed using SAS version 9.1 statistical software (SAS Institute, Cary, North Carolina).

Table 1 gives selected demographic, lifestyle, and clinical characteristics among 133 patients with BCRL and 864 patients without BCRL in the cohort. Women with BCRL were younger (55.3 years vs 60.1 years), more educated (58.6% vs 44.9% had completed college and/or graduate school), and were less likely to have smoked (63.9% vs 50.6%) compared with patients without BCRL. Patients with BCRL had more advanced cancer at diagnosis (AJCC stage II or III); were more likely to have had a mastectomy (58.6% vs 34.6%), ALND (86.5% vs 72.1%), or SLNB (84.2% vs 71.4%); and were more likely to have had radiation therapy (77.4% vs 70.3%) or chemotherapy (74.4% vs 39.7%) compared with patients without BCRL. On average, women with BCRL had had more lymph nodes removed (12.4 vs 6.1) and more positive lymph nodes (3.3 vs 0.8) compared with women without BCRL. No significant differences were observed between the 2 groups according to race/ethnicity, marital status, household income, BMI, physical activity, or adjuvant hormone therapy.

Table Graphic Jump LocationTable 1. Demographic, Lifestyle, and Clinical Characteristics of the Pathways Study Cohort by BCRL Status as of July 31, 2008a

Among the 997 women who received follow-up for a mean period of 20.9 months (range, 0.7-31.8 months) after breast cancer diagnosis, 133 women (13.3%) had a clinical indication for BCRL with a mean time to diagnosis of 8.3 months (range, 0.7-27.3 months) (Figure). At 12 and 24 months after breast cancer diagnosis, the cumulative incidence of BCRL was 10.4% and 13.5%, respectively.

Place holder to copy figure label and caption
Figure.

Cumulative incidence function estimates, derived from the Kaplan-Meier method, for occurrence of breast cancer–related lymphedema (BCRL) in the Pathways Study cohort as of July 31, 2008. The BCRL events indicate transient and persistent BCRL diagnosis from Kaiser Permanente Northern California electronic data sources, as defined by outpatient clinic or hospitalization diagnosis, BCRL procedure, or durable medical equipment order anytime after breast cancer diagnosis (total number of BCRL events = 133; mean time to diagnosis = 8.3 months; range, 0.7-27.3 months; interquartile range, 3.8-11.0 months).

Graphic Jump Location

Table 2 presents the associations between demographic, lifestyle, and clinical characteristics and risk of BCRL, adjusted for all characteristics of interest in 3 multivariate proportional hazards models. For model 1, which determined the risk of transient and persistent BCRL, African American women had an increased risk of BCRL compared with white women (HR, 1.93; 95% CI, 1.00-3.72). The risk appeared to be increased in other minority groups as well but was not statistically significant (Asian Americans: HR, 1.65; 95% CI, 0.88-3.10; other races or ethnicities: HR, 1.77; 95% CI, 0.73-4.25). Compared with women who had a high school education or less, women with a college education or higher had an increased risk of BCRL (college education: HR, 2.58; 95% CI, 1.18-5.63; postgraduate education: HR, 2.72; 95% CI, 1.21-6.11; P for trend = .03). Higher BMI was suggestive of an increased risk of BCRL among obese women (HR, 1.43; 95% CI, 0.88-2.31), yet results of the test for trend were not significant. Overall physical activity and moderate to vigorous physical activity were not associated with risk of BCRL.

Table Graphic Jump LocationTable 2. Associations of Demographic, Lifestyle, and Clinical Characteristics With Risk of BCRL in the Pathways Study Cohort as of July 31, 2008

Among the clinical characteristics, women diagnosed as having a more advanced cancer stage had an increased risk of BCRL (AJCC stage II: HR, 2.58; 95% CI, 1.43-4.65; AJCC stage III: HR, 5.39; 95% CI, 2.47-11.75). In addition, for each lymph node removed, BCRL risk increased by 4.1% (corresponding to a 49.3% increase in risk for every 10 nodes removed). Elevated yet nonsignificant associations were observed for mastectomy (HR, 1.29; 95% CI, 0.77-2.16) and lymph node dissection (axillary: HR, 1.37; 95% CI, 0.44-4.28; sentinel: HR, 1.54; 95% CI, 0.49-4.86; axillary and sentinel: HR, 1.75; 95% CI, 0.62-4.94). Chemotherapy (HR, 1.38; 95% CI, 0.81-2.38) and radiation therapy (HR, 1.25; 95% CI, 0.70-2.25) were associated with modestly increased risks of BCRL, whereas hormone therapy was not associated with risk (HR, 0.96; 95% CI, 0.62-1.47).

Similar associations with generally wider CIs were observed in models 2 and 3 regarding risk of persistent BCRL compared with model 1, although some differences were apparent (Table 2). In model 2, chemotherapy was significantly associated with risk of BCRL (HR, 2.04; 95% CI, 1.03-4.03) compared with model 1 (HR, 1.38; 95% CI, 0.81-2.38). For model 3, being obese was significantly associated with an increased risk of BCRL (HR, 2.34; 95% CI, 1.23-4.44) compared with model 1 (HR, 1.43; 95% CI, 0.88-2.31).

In this prospective cohort study of 997 breast cancer survivors who received follow-up for BCRL development for a mean period of 20.9 months, 133 women (13.3%) developed BCRL—as defined by a clinical diagnosis, procedure, or DME order—with a mean time to diagnosis of 8.3 months. Being African American and more educated was associated with an increased risk of BCRL. Advanced-stage breast cancer and number of lymph nodes removed were also associated with an increased risk of BCRL, although no significant association was observed for mastectomy and type of lymph node surgery. Smoking status and physical activity were not associated with BCRL risk, but being obese was suggestive of an elevated risk. After restricting BCRL diagnoses to exclude any transient swelling that might be treated as BCRL, all of the associations remained, with a stronger association of BCRL with obesity and chemotherapy.

Our results confirm and contrast with findings from 2 recent studies of BCRL.6,28 Paskett et al6 conducted a prospective study of 622 young breast cancer survivors (≤45 years at diagnosis) using semiannual questionnaires and assessed factors associated with incidence of arm and/or hand swelling using adjusted Cox proportional hazards models. Similar to our results, the authors found that lymph node removal was associated with an increased risk of swelling (for each node removed, HR, 1.02; 95% CI, 1.01-1.04). They observed that receiving chemotherapy (HR, 1.76; 95% CI, 1.10-2.82), being obese (HR, 1.51; 95% CI, 1.09-2.09), and being married (HR, 1.36; 95% CI, 1.00-1.85) were also associated with an elevated risk, whereas age at breast cancer diagnosis (HR, 1.00; 95% CI, 0.97-1.03) and radiation therapy (HR, 1.23; 95% CI, 0.86-1.77) were not associated with risk. With the exception of marital status, those findings are similar to ours.

Hayes et al28 evaluated 287 women between 6 and 18 months after breast cancer treatment for BCRL using bioimpedance spectroscopy and assessed the associations of personal, treatment, and behavioral characteristics with BCRL risk in adjusted logistic regression models. Similar to our study, they observed that removal of lymph nodes was associated with an increased risk (odds ration [OR], 3.9; 95% CI, 0.5-28.9) and that radiation therapy was not associated with risk (OR, 0.9; 95% CI, 0.2-4.3). In contrast to our null results, Hayes and colleagues observed that lower income (<$52 000 per year) was associated with a decreased risk (OR, 0.2; 95% CI, 0.1-0.5), whereas having a mastectomy (OR, 5.9; 95% CI, 1.4-22.5) and being at least 50 years old at cancer diagnosis (OR, 3.3; 95% CI, 1.0-11.1) were associated with an increased risk. They also reported that leading a sedentary lifestyle (OR, 6.1; 95% CI, 1.3-27.6) was associated with an increased risk of BCRL, thus suggesting, along with several studies observing no increase in symptoms after participating in various exercise programs,2933 that it is safe for women with BCRL to engage in physical activity.

The generally consistent findings across these studies and ours suggest that educational attainment, BMI, and lymph node removal may be risk factors for BCRL. The association of greater BCRL risk with higher educational level may be due to increased clinical consultation for swelling by more educated women, thereby resulting in additional BCRL diagnoses. Weight status at breast cancer diagnosis might be a predictor of developing BCRL, also suggested by other studies6,3436; obesity can contribute to an increased risk of postoperative complications and reduced muscle-pumping efficiency within loose tissues.34,37 As for chemotherapy, glucocorticoid agents such as dexamethasone can produce the adverse effect of swelling,38,39 which may also increase BCRL risk.

Removal of lymph nodes, rather than type of lymph node surgery, may be more germane to the risk of BCRL. Observational studies have documented a lower risk of BCRL and other arm morbidity symptoms among patients who underwent SLNB only compared with ALND.4046 For example, Francis et al46 observed a 16.8% incidence of BCRL after SLNB using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 criteria for diagnosis compared with an increased risk of 47.1% after ALND. In contrast, no difference in risk at 1 year of follow-up was observed between women who underwent SLNB and ALND compared with SLNB alone in the American College of Surgeons Oncology Group randomized clinical trial.47 Final results from the National Surgical Adjuvant Breast and Bowel Project clinical trial of more than 5500 patients with breast cancer are still outstanding.48 Although the evidence suggests that SLNB compared with ALND is associated with a lower risk of BCRL,49 likely owing to fewer lymph nodes removed with SLNB, we found that even with 1 removed node, a woman is at an increased risk (4.1%) for BCRL. Similarly, in a retrospective study of 1338 older patients with breast cancer who were diagnosed as having in situ or invasive cancer and self-reported having BCRL, an increased risk of BCRL was observed with successive removal of nodes but not according to type of surgery.50

To our knowledge, ours is the first study to report an elevated risk of BCRL among minority groups, specifically African Americans, independent of confounding factors such as age at diagnosis, breast cancer stage, and socioeconomic status (educational level and household income). Although we cannot completely rule out residual confounding and spurious results due to small sample size in our analysis, 1 retrospective study noted a higher prevalence of BCRL among women from minority backgrounds.51 This racial/ethnic difference is consistent with the hypothesis that, compared with white women, women from minority groups may be more likely to do manual labor involving the upper body and to return to work before full recovery and/or arm rehabilitation after their breast cancer surgery.

Strengths of this study include being one of the few large prospective cohort studies of BCRL and being conducted within KPNC, one of the largest health maintenance organizations in the United States with electronic medical records, facilitating rapid case ascertainment, participant follow-up, and identification of BCRL. We assessed BCRL by clinical indication using standard diagnostic and procedural codes. Furthermore, as part of a prospective study of breast cancer survivorship, we were able to examine the associations between demographic, lifestyle, and clinical characteristics and risk of BCRL.

Several limitations should be noted. First, we could examine only the effect of overall radiation therapy, rather than radiation therapy to the axilla, owing to a lack of information on the anatomical site of treatment in our electronic data sources. Second, considering our outcome ascertainment methods using electronic medical records, we could have missed underlying BCRL cases not brought to the attention of, or not diagnosed by, a health care professional and therefore not documented in the data sources. Conversely, we could have included BCRL cases diagnosed for preventive or evaluative purposes only, although when we limited our definition of BCRL diagnosis to outcomes of likely persistent BCRL, most of the associations remained.

In conclusion, our findings confirm the results of previous studies, especially those concerning the increased risk of BCRL with removal of lymph nodes and being obese. Although we did not examine change in BMI, management of body weight may be one avenue for decreasing the risk of BCRL. We also observed an increased risk among minority groups, specifically African American women, compared with white patients, and reasons for these differences need to be pursued. Considering the functional and psychosocial effects of developing BCRL, instituting educational programs that include a detailed clinical profile of identified risk factors before surgery might lead to improved prevention and treatment of this debilitating condition.

Correspondence: Marilyn L. Kwan, PhD, Division of Research, Kaiser Permanente Northern California, 2000 Broadway, First Floor, Oakland, CA 94612 (Marilyn.L.Kwan@kp.org).

Accepted for Publication: September 2, 2009.

Author Contributions:Study concept and design: Kwan and Kushi. Acquisition of data: Kwan, Darbinian, Citron, Partee, and Kushi. Analysis and interpretation of data: Kwan, Darbinian, Schmitz, Kutner, and Kushi. Drafting of the manuscript: Kwan and Darbinian. Critical revision of the manuscript for important intellectual content: Kwan, Darbinian, Schmitz, Citron, Partee, Kutner, and Kushi. Statistical analysis: Kwan and Darbinian. Obtained funding: Kwan and Kushi. Administrative, technical, and material support: Kwan, Darbinian, Citron, Partee, Kutner, and Kushi. Study supervision: Kwan and Kushi.

Financial Disclosure: None reported.

Funding/Support: This study was supported by grant R01 CA105274 from the National Cancer Institute (Dr Kushi) and grant RSG-06-209-01-LR from the American Cancer Society (Dr Kwan).

Disclaimer: The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies.

Additional Contributions: We gratefully acknowledge Bruce Fireman, MA, for biostatistical support; Erin Weltzien, BA, and Isaac Joshua Ergas, MPH, for programming assistance; the Pathways Study office and field staff; and most important, the Pathways Study participants.

 American Cancer Society. http://www.cancer.org/. Accessed April 12, 2008
Erickson  VSPearson  MLGanz  PAAdams  JKahn  KL Arm edema in breast cancer patients. J Natl Cancer Inst 2001;93 (2) 96- 111
PubMed
Petrek  JAPressman  PISmith  RA Lymphedema: current issues in research and management. CA Cancer J Clin 2000;50 (5) 292- 307
PubMed
Armer  JM The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest 2005;23 (1) 76- 83
PubMed
 National Lymphedema Network. http://www.lymphnet.org/. Accessed April 12, 2008
Paskett  EDNaughton  MJMcCoy  TPCase  LDAbbott  JM The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev 2007;16 (4) 775- 782
PubMed
Petrek  JAHeelan  MC Incidence of breast carcinoma-related lymphedema. Cancer 1998;83 (12, suppl American) 2776- 2781
PubMed
Humble  CA Lymphedema: incidence, pathophysiology, management, and nursing care. Oncol Nurs Forum 1995;22 (10) 1503- 1509
PubMed
McWayne  JHeiney  SP Psychologic and social sequelae of secondary lymphedema: a review. Cancer 2005;104 (3) 457- 466
PubMed
Segerström  KBjerle  PNyström  A Importance of time in assessing arm and hand function after treatment of breast cancer. Scand J Plast Reconstr Surg Hand Surg 1991;25 (3) 241- 244
PubMed
Tobin  MBLacey  HJMeyer  LMortimer  PS The psychological morbidity of breast cancer-related arm swelling: psychological morbidity of lymphoedema. Cancer 1993;72 (11) 3248- 3252
PubMed
Maunsell  EBrisson  JDeschênes  L Arm problems and psychological distress after surgery for breast cancer. Can J Surg 1993;36 (4) 315- 320
PubMed
Velanovich  VSzymanski  W Quality of life of breast cancer patients with lymphedema. Am J Surg 1999;177 (3) 184- 188
PubMed
Passik  SNewman  MBrennan  MHolland  J Psychiatric consultation for women undergoing rehabilitation for upper-extremity lymphedema following breast cancer treatment. J Pain Symptom Manage 1993;8 (4) 226- 233
PubMed
Engel  JKerr  JSchlesinger-Raab  ASauer  HHölzel  D Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients. Breast Cancer Res Treat 2003;79 (1) 47- 57
PubMed
Kwan  WJackson  JWeir  LMDingee  CMcGregor  GOlivotto  IA Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002;20 (20) 4242- 4248
PubMed
Kornblith  ABHerndon  JE  IIWeiss  RB  et al.  Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer 2003;98 (4) 679- 689
PubMed
Ahmed  RLPrizment  ALazovich  DSchmitz  KHFolsom  AR Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study [published online ahead of print November 10, 2008]. J Clin Oncol 2008;26 (35) 5689- 5696
PubMed10.1200/JCO.2008.16.4731
Kwan  MLAmbrosone  CBLee  MM  et al.  The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California [published online ahead of print May 14, 2008]. Cancer Causes Control 2008;19 (10) 1065- 1076
PubMed10.1007/s10552-008-9170-5
Harwood  CAMortimer  PS Causes and clinical manifestations of lymphatic failure. Clin Dermatol 1995;13 (5) 459- 471
PubMed
Cheville  ALMcGarvey  CLPetrek  JARusso  SAThiadens  SRTaylor  ME The grading of lymphedema in oncology clinical trials. Semin Radiat Oncol 2003;13 (3) 214- 225
PubMed
National Lymphedema Network Medical Advisory Committee, Training of lymphedema therapists. http://www.lymphnet.org/lymphedemaFAQs/positionPapers.htm. Accessed December 22, 2008
World Health Organization, International Classification of Diseases, Ninth Revision (ICD-9).  Geneva, Switzerland World Health Organization1977;
Staten  LKTaren  DLHowell  WH  et al.  Validation of the Arizona Activity Frequency Questionnaire using doubly labeled water. Med Sci Sports Exerc 2001;33 (11) 1959- 1967
PubMed
Oehrli  MDQuesenberry  CPLeyden  W 2006 Annual Report on Trends, Incidence, and Outcomes.  Oakland Kaiser Permanente Northern California Cancer Registry2006;
Kaplan  ELMeier  P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53457- 481
Cox  DROakes  D Analysis of Survival Data.  New York, NY Chapman & Hall1994;
Hayes  SCJanda  MCornish  BBattistutta  DNewman  B Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol 2008;26 (21) 3536- 3542
PubMed
Harris  SRNiesen-Vertommen  SL Challenging the myth of exercise-induced lymphedema following breast cancer: a series of case reports. J Surg Oncol 2000;74 (2) 95- 99
PubMed
Turner  JHayes  SReul-Hirche  H Improving the physical status and quality of life of women treated for breast cancer: a pilot study of a structured exercise intervention. J Surg Oncol 2004;86 (3) 141- 146
PubMed
McKenzie  DCKalda  AL Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: a pilot study. J Clin Oncol 2003;21 (3) 463- 466
PubMed
Ahmed  RLThomas  WYee  DSchmitz  KH Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J Clin Oncol 2006;24 (18) 2765- 2772
PubMed
Schmitz  KHAhmed  RLTroxel  A  et al.  Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med 2009;361 (7) 664- 673
PubMed
Clark  BSitzia  JHarlow  W Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study [published online ahead of print April 8, 2005]. QJM 2005;98 (5) 343- 348
PubMed10.1093/qjmed/hci053
Soran  AD’Angelo  GBegovic  M  et al.  Breast cancer-related lymphedema: what are the significant predictors and how they affect the severity of lymphedema? Breast J 2006;12 (6) 536- 543
PubMed
Werner  RSMcCormick  BPetrek  J  et al.  Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 1991;180 (1) 177- 184
PubMed
Brorson  H Adipose tissue in lymphedema: the ignorance of adipose tissue in lymphedema. Lymphology 2004;37 (4) 175- 177
PubMed
 American Cancer Society. http://www.cancer.org/docroot/CDG/content/CDG_dexamethasone.asp. Accessed December 22, 2008
Walsh  DAvashia  J Glucocorticoids in clinical oncology. Cleve Clin J Med 1992;59 (5) 505- 515
PubMed
Schrenk  PRieger  RShamiyeh  AWayand  W Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88 (3) 608- 614
PubMed
Purushotham  ADUpponi  SKlevesath  MB  et al.  Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005;23 (19) 4312- 4321
PubMed
Helms  GKuhn  TMoser  LRemmel  EKreienberg  R Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection: data from a prospective randomised trial [published online ahead of print October 5, 2008]. Eur J Surg Oncol 2009;35 (7) 696- 701
PubMed
Schulze  TMucke  JMarkwardt  JSchlag  PMBembenek  A Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 2006;93 (2) 109- 119
PubMed
Husted Madsen  AHaugaard  KSoerensen  J  et al.  Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast 2008;17 (2) 138- 147
PubMed
McLaughlin  SAWright  MJMorris  KT  et al.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements [published online ahead of print October 6, 2008]. J Clin Oncol 2008;26 (32) 5213- 5219
PubMed10.1200/JCO.2008.16.3725
Francis  WPAbghari  PDu  WRymal  CSuna  MKosir  MA Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am J Surg 2006;192 (5) 636- 639
PubMed
Lucci  AMcCall  LMBeitsch  PD  et al. American College of Surgeons Oncology Group, Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011 [published online ahead of print May 7, 2007]. J Clin Oncol 2007;25 (24) 3657- 3663
PubMed10.1200/JCO.2006.07.4062
Krag  DNAnderson  SJJulian  TB  et al. National Surgical Adjuvant Breast and Bowel Project, Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8 (10) 881- 888
PubMed
Cochran  AJRoberts  AASaida  T The place of lymphatic mapping and sentinel node biopsy in oncology. Int J Clin Oncol 2003;8 (3) 139- 150
PubMed
Yen  TWFan  XSparapani  RLaud  PWWalker  APNattinger  ABA A contemporary, population-based study of lymphedema risk factors in older women with breast cancer [published online ahead of print February 5, 2009]. Ann Surg Oncol 2009;16 (4) 979- 988
PubMed10.1245/s10434-009-0347-2
Eversley  REstrin  DDibble  SWardlaw  LPedrosa  MFavila-Penney  W Post-treatment symptoms among ethnic minority breast cancer survivors. Oncol Nurs Forum 2005;32 (2) 250- 256
PubMed

Figures

Place holder to copy figure label and caption
Figure.

Cumulative incidence function estimates, derived from the Kaplan-Meier method, for occurrence of breast cancer–related lymphedema (BCRL) in the Pathways Study cohort as of July 31, 2008. The BCRL events indicate transient and persistent BCRL diagnosis from Kaiser Permanente Northern California electronic data sources, as defined by outpatient clinic or hospitalization diagnosis, BCRL procedure, or durable medical equipment order anytime after breast cancer diagnosis (total number of BCRL events = 133; mean time to diagnosis = 8.3 months; range, 0.7-27.3 months; interquartile range, 3.8-11.0 months).

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Demographic, Lifestyle, and Clinical Characteristics of the Pathways Study Cohort by BCRL Status as of July 31, 2008a
Table Graphic Jump LocationTable 2. Associations of Demographic, Lifestyle, and Clinical Characteristics With Risk of BCRL in the Pathways Study Cohort as of July 31, 2008

References

 American Cancer Society. http://www.cancer.org/. Accessed April 12, 2008
Erickson  VSPearson  MLGanz  PAAdams  JKahn  KL Arm edema in breast cancer patients. J Natl Cancer Inst 2001;93 (2) 96- 111
PubMed
Petrek  JAPressman  PISmith  RA Lymphedema: current issues in research and management. CA Cancer J Clin 2000;50 (5) 292- 307
PubMed
Armer  JM The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest 2005;23 (1) 76- 83
PubMed
 National Lymphedema Network. http://www.lymphnet.org/. Accessed April 12, 2008
Paskett  EDNaughton  MJMcCoy  TPCase  LDAbbott  JM The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev 2007;16 (4) 775- 782
PubMed
Petrek  JAHeelan  MC Incidence of breast carcinoma-related lymphedema. Cancer 1998;83 (12, suppl American) 2776- 2781
PubMed
Humble  CA Lymphedema: incidence, pathophysiology, management, and nursing care. Oncol Nurs Forum 1995;22 (10) 1503- 1509
PubMed
McWayne  JHeiney  SP Psychologic and social sequelae of secondary lymphedema: a review. Cancer 2005;104 (3) 457- 466
PubMed
Segerström  KBjerle  PNyström  A Importance of time in assessing arm and hand function after treatment of breast cancer. Scand J Plast Reconstr Surg Hand Surg 1991;25 (3) 241- 244
PubMed
Tobin  MBLacey  HJMeyer  LMortimer  PS The psychological morbidity of breast cancer-related arm swelling: psychological morbidity of lymphoedema. Cancer 1993;72 (11) 3248- 3252
PubMed
Maunsell  EBrisson  JDeschênes  L Arm problems and psychological distress after surgery for breast cancer. Can J Surg 1993;36 (4) 315- 320
PubMed
Velanovich  VSzymanski  W Quality of life of breast cancer patients with lymphedema. Am J Surg 1999;177 (3) 184- 188
PubMed
Passik  SNewman  MBrennan  MHolland  J Psychiatric consultation for women undergoing rehabilitation for upper-extremity lymphedema following breast cancer treatment. J Pain Symptom Manage 1993;8 (4) 226- 233
PubMed
Engel  JKerr  JSchlesinger-Raab  ASauer  HHölzel  D Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients. Breast Cancer Res Treat 2003;79 (1) 47- 57
PubMed
Kwan  WJackson  JWeir  LMDingee  CMcGregor  GOlivotto  IA Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002;20 (20) 4242- 4248
PubMed
Kornblith  ABHerndon  JE  IIWeiss  RB  et al.  Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer 2003;98 (4) 679- 689
PubMed
Ahmed  RLPrizment  ALazovich  DSchmitz  KHFolsom  AR Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study [published online ahead of print November 10, 2008]. J Clin Oncol 2008;26 (35) 5689- 5696
PubMed10.1200/JCO.2008.16.4731
Kwan  MLAmbrosone  CBLee  MM  et al.  The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California [published online ahead of print May 14, 2008]. Cancer Causes Control 2008;19 (10) 1065- 1076
PubMed10.1007/s10552-008-9170-5
Harwood  CAMortimer  PS Causes and clinical manifestations of lymphatic failure. Clin Dermatol 1995;13 (5) 459- 471
PubMed
Cheville  ALMcGarvey  CLPetrek  JARusso  SAThiadens  SRTaylor  ME The grading of lymphedema in oncology clinical trials. Semin Radiat Oncol 2003;13 (3) 214- 225
PubMed
National Lymphedema Network Medical Advisory Committee, Training of lymphedema therapists. http://www.lymphnet.org/lymphedemaFAQs/positionPapers.htm. Accessed December 22, 2008
World Health Organization, International Classification of Diseases, Ninth Revision (ICD-9).  Geneva, Switzerland World Health Organization1977;
Staten  LKTaren  DLHowell  WH  et al.  Validation of the Arizona Activity Frequency Questionnaire using doubly labeled water. Med Sci Sports Exerc 2001;33 (11) 1959- 1967
PubMed
Oehrli  MDQuesenberry  CPLeyden  W 2006 Annual Report on Trends, Incidence, and Outcomes.  Oakland Kaiser Permanente Northern California Cancer Registry2006;
Kaplan  ELMeier  P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53457- 481
Cox  DROakes  D Analysis of Survival Data.  New York, NY Chapman & Hall1994;
Hayes  SCJanda  MCornish  BBattistutta  DNewman  B Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol 2008;26 (21) 3536- 3542
PubMed
Harris  SRNiesen-Vertommen  SL Challenging the myth of exercise-induced lymphedema following breast cancer: a series of case reports. J Surg Oncol 2000;74 (2) 95- 99
PubMed
Turner  JHayes  SReul-Hirche  H Improving the physical status and quality of life of women treated for breast cancer: a pilot study of a structured exercise intervention. J Surg Oncol 2004;86 (3) 141- 146
PubMed
McKenzie  DCKalda  AL Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: a pilot study. J Clin Oncol 2003;21 (3) 463- 466
PubMed
Ahmed  RLThomas  WYee  DSchmitz  KH Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J Clin Oncol 2006;24 (18) 2765- 2772
PubMed
Schmitz  KHAhmed  RLTroxel  A  et al.  Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med 2009;361 (7) 664- 673
PubMed
Clark  BSitzia  JHarlow  W Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study [published online ahead of print April 8, 2005]. QJM 2005;98 (5) 343- 348
PubMed10.1093/qjmed/hci053
Soran  AD’Angelo  GBegovic  M  et al.  Breast cancer-related lymphedema: what are the significant predictors and how they affect the severity of lymphedema? Breast J 2006;12 (6) 536- 543
PubMed
Werner  RSMcCormick  BPetrek  J  et al.  Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 1991;180 (1) 177- 184
PubMed
Brorson  H Adipose tissue in lymphedema: the ignorance of adipose tissue in lymphedema. Lymphology 2004;37 (4) 175- 177
PubMed
 American Cancer Society. http://www.cancer.org/docroot/CDG/content/CDG_dexamethasone.asp. Accessed December 22, 2008
Walsh  DAvashia  J Glucocorticoids in clinical oncology. Cleve Clin J Med 1992;59 (5) 505- 515
PubMed
Schrenk  PRieger  RShamiyeh  AWayand  W Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88 (3) 608- 614
PubMed
Purushotham  ADUpponi  SKlevesath  MB  et al.  Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005;23 (19) 4312- 4321
PubMed
Helms  GKuhn  TMoser  LRemmel  EKreienberg  R Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection: data from a prospective randomised trial [published online ahead of print October 5, 2008]. Eur J Surg Oncol 2009;35 (7) 696- 701
PubMed
Schulze  TMucke  JMarkwardt  JSchlag  PMBembenek  A Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 2006;93 (2) 109- 119
PubMed
Husted Madsen  AHaugaard  KSoerensen  J  et al.  Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast 2008;17 (2) 138- 147
PubMed
McLaughlin  SAWright  MJMorris  KT  et al.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements [published online ahead of print October 6, 2008]. J Clin Oncol 2008;26 (32) 5213- 5219
PubMed10.1200/JCO.2008.16.3725
Francis  WPAbghari  PDu  WRymal  CSuna  MKosir  MA Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am J Surg 2006;192 (5) 636- 639
PubMed
Lucci  AMcCall  LMBeitsch  PD  et al. American College of Surgeons Oncology Group, Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011 [published online ahead of print May 7, 2007]. J Clin Oncol 2007;25 (24) 3657- 3663
PubMed10.1200/JCO.2006.07.4062
Krag  DNAnderson  SJJulian  TB  et al. National Surgical Adjuvant Breast and Bowel Project, Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8 (10) 881- 888
PubMed
Cochran  AJRoberts  AASaida  T The place of lymphatic mapping and sentinel node biopsy in oncology. Int J Clin Oncol 2003;8 (3) 139- 150
PubMed
Yen  TWFan  XSparapani  RLaud  PWWalker  APNattinger  ABA A contemporary, population-based study of lymphedema risk factors in older women with breast cancer [published online ahead of print February 5, 2009]. Ann Surg Oncol 2009;16 (4) 979- 988
PubMed10.1245/s10434-009-0347-2
Eversley  REstrin  DDibble  SWardlaw  LPedrosa  MFavila-Penney  W Post-treatment symptoms among ethnic minority breast cancer survivors. Oncol Nurs Forum 2005;32 (2) 250- 256
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 28

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles